This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Acquiring insight into the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction to patients with primary hyperlipidemia.

Ticker(s): NVS

Who's the expert?

Institution: Columbia University

  • Chief of vascular surgery at NewYork-Presbyterian/Columbia University Irving Medical Center. 
  • A vascular surgeon-scientist, Dr. Patel is highly skilled in the full range of vascular disorders that can lead to stroke, renal issues, intestinal problems, and peripheral arterial disease.
  •  Interest in clinical outcomes research and has served as principal investigator of several studies to evaluate open and minimally invasive repairs of complex aortic aneurysms.
  • Manages 10-15 patients monthly with Paroxysmal supraventricular tachycardia (PSVT)

Interview Goal
To discuss the current standard of care and the recent label expansion of Novartis' Leqvio (inclisiran) for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C).

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.